Una vida dedicada a l’hemofília, reconeguda com a referent nacional i internacional
Obra Publicada
Llibres
- Altisent C. Hemofilia: diagnóstico y clasificación. A: Soto I, Álvarez MT (editores). Hemostasia y trombosis en la pràctica clínica. Madrid, Ergon, 2018, 141-150.
- Altisent C, Álvarez-Román MT. Recomendaciones para el diagnóstico y tratamiento de la hemofilia adquirida en España. Ambos Marketing Services, Barcelona, 2017.
- Altisent C. Coagulopatías congénitas. A: Moro M, Málaga S, Madero L (editores). Cruz. Tratado de Pediatría, 11ª ed, tomo 2. Madrid, Panamericana, 2014, 1.882-1.890.
- Altisent C. Cirugía. En: Jiménez V (ed). Atlas de hemofília. Salerno, Momento Médico, 2013, 73-81.
- Altisent C, Vidal F. Perinatal clinical care and molecular diagnosis in hemophilia. A: Rodríguez Merchán C, Valentino LA. Current and future issues in hemophilia care. Chichester (UK), Wiley-Blackwell, 2011, 39-43.
- Altisent C. Fisiopatología de la artropatia. En: Jiménez V (ed). Inhibidores en hemofília. Madrid, Momento Médico Iberoamericana, 2009, 115-124.
- Puig Ll, Altisent C, Martorell M et al. Aspectos clínicos de la hemofília. A: Manual de hemofília para adultos. Fundació Privada Catalana de l’Hemofília. Barcelona, 2002, 11-50.
- Gallardo D, Vidal F, Altisent C. Diagnóstico molecular. Estudio de portadores y consejo genético. A: Batlle J, Rocha E. Guía práctica de coagulopatías congénitas. Madrid, Acción Médica, 2001, 35-48.
- Nolla R, Altisent C, Finestres JM et al. Les metahemoglobinèmies. Monografies mèdiques de l’Acadèmia. Barcelona, 1979.
Articles, els més rellevants dels últims cinc anys:
- Liesner RJ, Abraham A, Altisent C et al. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thromb Haemost. 2021; 121 (11):1400-1408.
- Pérez-Rodríguez A, Batlle J, Pinto JC, Corrales I, Borràs N, Garcia-Martínez I, Cid AR, Bonanad S, Parra R, Mingot-Castellano ME, Navarro N, Altisent C et al. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project. Haemophilia. 2021; 27 (6):1007-1021.
- Garcia-Martínez I, Borràs N, Martorell M, Parra R, Altisent C et al. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. Thromb Haemost. 2020; 120 (10): 1395-1406.
- Borràs N, Garcia-Martínez I, Batlle J, Pérez-Rodríguez A, Parra R, Altisent C et al. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort. Thromb Haemost. 2020;120 (3): 437-448.
- Mancuso ME, Oldenburg J, Boggio L, Kenet G, Chan A, Altisent C et al. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice. Haemophilia. 2020; 26 (4): 637-642.
- Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C et al. Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA. Haematologica. 2019; 104 (3): 587-598.
- De la Morena-Barrio ME, Salloum-Asfar S, Esteban J, de la Morena-Barrio B, Altisent C et al. Archeogenetics of F11 p.Cys38Arg: a 5400-year-old mutation identified in different southwestern European countries. Blood. 2019; 133 (24): 2618-2622.
- Pardos-Gea J, Fernández-Díaz N, Parra R, Cortina V, Altisent C. Diagnostic delay in acquired haemophilia: Analysis of causes and consequences in a 20-year Spanish cohort. Haemophilia. 2018; 24 (3): e163-e166.
- Carcao M, Altisent C, Castaman G et al. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018; 118 (3): 451-460.
- Aznar JA, Altisent C, Álvarez-Román MT et al. Moderate and severe haemophilia in Spain: An epidemiological update. Haemophilia. 2018; 24 (3): e136-e139.
- Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016; 127 (14):1761-9.
- Altisent C, Martorell M, Crespo A et al. Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes. Haemophilia. 2016; 22 (2): 218-224.
- Windyga J, Dolan G, Altisent C et al. EHTSB. Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. Haemophilia. 2016; 22 (5):739-51.
- Altisent C, Martorell M, Crespo A et al. Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes. Haemophilia. 2016; 22 (2): 218-224.
- Altisent C, Martorell M, de la Sierra A. Sodium content in products used to treat haemophilia. Haemophilia. 2016; 22 (4): e324-7.
- Windyga J, Dolan G, Altisent C et al. Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey. Haemophilia. 2016; 22 (1):110-120.
